{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T04:08:07Z","timestamp":1749787687869,"version":"3.41.0"},"reference-count":12,"publisher":"American Society of Hematology","issue":"24","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,6,12]]},"abstract":"<jats:sec>\n                  <jats:title\/>\n                  <jats:p>Recent molecular and diagnostic advances in acute myeloid leukemia (AML) have led investigators and clinicians to further categorize patients in different subgroups, guiding therapeutic interventions. Associate Editor Selina Luger introduces this 4-piece Blood Spotlight series that she commissioned from leaders in the field and that focuses on these specific patients\u2019 subgroups, not only on recent therapeutic advances but also on identifying areas of unmet need. Sallman and Stahl discuss TP53-mutated myelodysplastic syndrome and AML, proposing a new treatment algorithm. Perl provides a comprehensive spotlight on the use of cytotoxic chemotherapy, FLT3 inhibitors, and transplantation for FLT3-mutated AML. Abedin et al focus on the treatment of AML in fit older patients, making a case for enrollment of such individuals in clinical trials. Last, Walter et al provide a thoughtful discussion of the state of allogeneic hematopoietic cell transplantation for patients with AML who are at least 70 years old.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/blood.2025028384","type":"journal-article","created":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T15:31:19Z","timestamp":1749742279000},"page":"2801-2802","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["Introduction to a <i>Blood<\/i> Spotlight series on acute myeloid leukemia"],"prefix":"10.1182","volume":"145","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3364-4366","authenticated-orcid":false,"given":"Selina M.","family":"Luger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"3","key":"2025061211311080800_bib1","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1182\/blood-2009-11-254441","article-title":"Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials","volume":"116","author":"Grimwade","year":"2010","journal-title":"Blood"},{"issue":"13","key":"2025061211311080800_bib2","doi-asserted-by":"crossref","first-page":"4075","DOI":"10.1182\/blood.V96.13.4075","article-title":"Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group\/Eastern Cooperative Oncology Group Study","volume":"96","author":"Slovak","year":"2000","journal-title":"Blood"},{"issue":"2","key":"2025061211311080800_bib3","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1046\/j.1365-2141.2002.03724.x","article-title":"The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial","volume":"118","author":"Burnett","year":"2002","journal-title":"Br J Haematol"},{"issue":"17","key":"2025061211311080800_bib4","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1200\/JCO.2011.39.6499","article-title":"Comparative analysis of the value of allogeneic hematopoietic stem-cell transplantation in acute myeloid leukemia with monosomal karyotype versus other cytogenetic risk categories","volume":"30","author":"Cornelissen","year":"2012","journal-title":"J Clin Oncol"},{"issue":"10","key":"2025061211311080800_bib5","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/nrclinonc.2012.150","article-title":"The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach","volume":"9","author":"Cornelissen","year":"2012","journal-title":"Nat Rev Clin Oncol"},{"issue":"18","key":"2025061211311080800_bib6","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa074306","article-title":"Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia","volume":"358","author":"Schlenk","year":"2008","journal-title":"N Engl J Med"},{"issue":"12","key":"2025061211311080800_bib7","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1056\/NEJMoa1112304","article-title":"Prognostic relevance of integrated genetic profiling in acute myeloid leukemia","volume":"366","author":"Patel","year":"2012","journal-title":"N Engl J Med"},{"issue":"23","key":"2025061211311080800_bib8","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med"},{"issue":"4","key":"2025061211311080800_bib9","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"issue":"5","key":"2025061211311080800_bib10","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"2025061211311080800_bib11","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1507471","article-title":"Assessment of minimal residual disease in standard-risk AML","volume":"374","author":"Ivey","year":"2016","journal-title":"N Engl J Med"},{"issue":"12","key":"2025061211311080800_bib12","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/145\/24\/2801\/2379069\/blood_bld-2025-028384-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/145\/24\/2801\/2379069\/blood_bld-2025-028384-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T15:31:21Z","timestamp":1749742281000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/145\/24\/2801\/537608\/Introduction-to-a-Blood-Spotlight-series-on-acute"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,12]]},"references-count":12,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2025,6,12]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2025028384","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,6,12]]},"published":{"date-parts":[[2025,6,12]]}}}